Contact:

At RegeneRx:
J.J. Finkelstein
jjfnk@regenerx.com
301.280.1992

At the Financial
Relations Board:
Analyst Inquiries:
Leslie Loyet
312.640.6672

or
General Inquiries
Kathy Waller
312.640.6696

RegeneRx Biopharmaceuticals, Inc. (AMEX:RGN), today announced that it will report fourth quarter and year end 2005 results before the market opens on Friday, March 31, 2006. The company will also conduct a conference call the same day at 11:00 a.m. Eastern Time to discuss the results and its outlook for 2006.

The conference call will be accessible by telephone and through the Internet. Interested individuals are invited to access the call by dialing 800-289-0494. To participate on the webcast, log on to the company's website at www.regenerx.com (go to the investor relations home page) or www.viavid.com 15 minutes before the call to download the necessary software.

For those unable to listen to the call live, a taped rebroadcast will be available beginning approximately two hours after completion of the live call on March 31, 2006 through April 7, 2006. To access the replay, dial 888-203-1112 and request reservation number 8645794. A replay of the call will also be available on the Internet at www.regenerx.com or www.viavid.com for 30 days.

About RegeneRx Biopharmaceuticals, Inc.
RegeneRx is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Currently, RegeneRx is developing TB4, a 43 amino acid peptide, under an exclusive world-wide license from the National Institutes of Health. Preliminary research suggests that TB4 may prove efficacious for multiple indications; therefore RegeneRx is developing TB4 as a therapeutic platform. RegeneRx holds over fifty world-wide patents and patent applications related to dermal, ocular, and internal wounds and tissue repair, cardiac and neurological injuries, and septic shock. RegeneRx is currently sponsoring three Phase II chronic dermal wound healing clinical trials and has additionally targeted ophthalmic and cardiac trials in 2006 as part of its ongoing clinical development program.

For more information please visit RegeneRx's web site at www.regenerx.com

SOURCE: RegeneRx Biopharmaceuticals, Inc.

Back To 2006 Press Release Archives